Fintepla 2.2 mg/ml
As listed in the register: Fintepla 2.2 mg/ml, solution buvable
2.2 mg/ml ·
- Prescription only
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Fenfluraminum
- Made by
- UCB-Pharma SA
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Traitement adjuvant des crises d'épilepsie associées au syndrome de Dravet (SD) ou au syndrome de Lennox-Gastaut (SLG), chez les patients de 2 ans et plus.
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | UCB-Pharma SA |
|---|---|
| Active substance | Fenfluraminum |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Strength | 2.2 mg/ml |
| Classification | N03AX26 · Pain, sleep, mood, epilepsy and the brain |
| Dispensing (as stated by the register) | Abgabekategorie A |
| Name in the register | Fintepla 2.2 mg/ml, solution buvable |
| Packs | 120 ml Flasche(n) · 360 ml Flasche(n) |
| Zulassungsnummer | 69371 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.